Highlights from EAU25 by Sabine Brookman-May

The 40th Annual European Association of Urology Congress (EAU25) is happening from March 21 to March 24, 2025, in Madrid, Spain.

Experts are performing live surgeries, delivering lectures, leading patient discussions, and conducting hands-on training through the European School of Urology. Scientists are presenting new research, while attendees are earning up to 28.00 CME credits.

On the exhibition floor, the latest urological technologies are being showcased. The European Association of Urology (EAU) is welcoming new members with discounted registration and career opportunities. Participants are also presenting abstracts, gaining recognition in the field.

Sabine Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared some insights from EAU25:

Paolo Gontero at EAU25

“Great talk by Paolo Gontero at EAU25.

• Radical Cystectomy still needed as pathological complete response pCR impacts survival MIBC
• clinical complete response criteria not validated and ‘Survival is the endpoint and not sex’ – maybe controversial – but without survival also no sex.”

Arguments for AS by Phillip Pierorazio and points for partial nephrectomy by Nina Harke

“Active Surveillance in Small Renal Masses SRM?

Great arguments for AS by Phillip Pierorazio (almost negligible risk of metastasis), but also reasonable points for partial nephrectomy provided by Nina Harke.”

How would a world without BCG look like?

“How would a world without BCG look like?

Pros for BCG outlined by Gianluca Giannarini: efficacy, costs and shortage not a problem.

Counterpart addressed by Laura S. Mertens: maintenance is most critical to generate efficacy and toxicity not negligible.”

ANZUP session covering various GU oncology topics

“Great ANZUP session covering various GU oncology topics at EAU2025.

Evanguelos Xylinas talking about bladder-sparing approaches in MIBC:

• Trimodal therapy is an option
• Complete TURBT is essential
• Studies are needed evaluating biomarker-driven strategies.”

Our current ph 1 trial with AU011 in NMIBC by Seth Lerner

“Looking forward to seeing the first data presented by Seth Lerner from our current ph 1 trial with AU011 in NMIBC

• Virus-like-Drug-Conjugates VDC as a potential dual MoA treatment approach
• EAU 3:30 pm Purple Area Room 1 Biomarkers and Novel Therapies.”

Neoadjuvant studies in Prostate Cancer by Martin Gleave

“Excellent talk about neoadjuvant studies in Prostate Cancer by Martin Gleave.

• No standard yet prior to RP
• Data from PROTEUS expected later this year
• GUNS trial as an adaptive biomarker-driven study with different neoadjuvant approaches.”

Lars Dyrskjøt on biomarkers in GU

“Very good talk by Lars Dyrskjøt on biomarkers in GU and hurdles to get them adopted in the biomarker session

Great panel overall.”

Imaging in Prostate and Bladder Cancer as predictive biomarker by Valeria Panebianco

“State of the art lecture on imaging in Prostate and Bladder Cancer as predictive biomarker by Valeria Panebianco.the 

• potential of nacVI-RADS in Bladder Cancer demonstrating optimal interreader variability
• use of virtual pathways and Digital Twins.”

Nazli Dizman reviews evidence and proof-of-concept trials on Biotherapeutics and immunotherapy combinations

“The microbiome plays an important role in RCC and impacts response to and outcomes of immunotherapies.

Nazli Dizman summarizing current evidence and showing proof of concept trials with combinations of Biotherapeutica and immune therapy.”

Seth Lerner presenting first data from phase 1 trial with AU011/belsar

“Seth Lerner presenting first data from phase 1 trial with AU011/belsar, a Virus-like-Drug-Conjugate VDC in IR/HR NMIBC

• Complete response in 4/5 IR NMIBC
• Field effect with response also in non-target lesions
• Strong Immune Response.”

More posts featuring Sabine Brookman-May.